All In Biotech

Drug Trial Radar · NCT05407636

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD

Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Title says "pivotal". Randomized with 735 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

735

Actual

Start

Jan 13, 2022

Primary completion

Oct 2026

Study completion Nov 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
Collaborators
REGENXBIO Inc.
First posted
Jun 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 89 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ABBV-RGX-314 (also known as RGX-314 and surabgene lomparvovec (sura-vec)) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (VEGF) therapies have significantly changed the landscape for treatment of wet AMD, becoming the standard of care due to their ability to prevent progression of vision loss in the majority of patients. These therapies, however, require life-long intraocular injections, typically repeated every four to 12 weeks in frequency, to maintain efficacy. Due to the burden of treatment, patients often experience a decline in vision with reduced frequency of treatment over time. ABBV-RGX-314 is being developed as a potential one-time treatment for wet AMD.

Conditions

  • AMD
  • nAMD
  • Wet Age-related Macular Degeneration
  • wAMD
  • WetAMD
  • CNV

Interventions

  • ABBV-RGX-314 Dose 1Genetic

    AAV8 vector containing a transgene for anti-VEGF Fab (Dose 1)

  • ABBV-RGX-314 Dose 2Genetic

    AAV8 vector containing a transgene for anti-VEGF Fab (Dose 2)

  • Aflibercept (EYLEA®)Biological

    2.0 mg (0.05 mLsolution) administered by intravitreal injection approximately every 8 weeks after 3 monthly injections

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from baseline in Best Corrected Visual Acuity (BCVA)Time frame: At Week 54
  2. Bilateral Treatment Substudy: Incidence of ocular AEs and any SAEsTime frame: Week 50

Locations

181 sites in 10 countries. Site status is shown where the registry gives one.

  • Barnet Dulaney Eye Center-Phoenix /ID# 256340

    Phoenix, Arizona

  • Retinal Research Institute /ID# 256238

    Phoenix, Arizona

  • Retina Macula Institute of Arizona /ID# 271026

    Scottsdale, Arizona

  • California Retina Consultants - Bakersfield /ID# 256240

    Bakersfield, California

  • Retina Vitreous Assoc Med Grp /ID# 256246

    Beverly Hills, California

  • Retinal Diagnostic Center /ID# 256262

    Campbell, California

  • The Retina Partners - Encino /ID# 259660

    Encino, California

  • Retina Consultants of Orange County /ID# 256267

    Fullerton, California

  • Jacobs Retina Center at UCSD/ID# 256320

    La Jolla, California

  • California Retina Consultants - Oxnard - North Ventura Road /ID# 262883

    Oxnard, California

  • Byers Eye Institute Stanford /ID# 262853

    Palo Alto, California

  • Retina Consultants of San Diego /ID# 256258

    Poway, California

  • Kaiser Permanente - Riverside Medical Center /ID# 262413

    Riverside, California

  • UC Davis Health Eye Center

    Sacramento, California

  • Retinal Consultants Medical Group, Inc. - Greenback /ID# 256353

    Sacramento, California

  • Orange County Retina Medical Group /ID# 256286

    Santa Ana, California

  • Macula Retina Vitreous Center - Torrance /ID# 270247

    Torrance, California

  • Bay Area Retina Associates - Walnut Creek - Lennon Lane /ID# 268513

    Walnut Creek, California

  • Retina Consultants of Southern Colorado /ID# 256285

    Colorado Springs, Colorado

  • Southwest Retina Research Center /ID# 256261

    Durango, Colorado

  • Colorado Retina Associates /ID# 256378

    Lakewood, Colorado

  • Advanced Vision Research Institute /ID# 256380

    Longmont, Colorado

  • Retina Consultants, P.C. /ID# 273610

    Manchester, Connecticut

  • Rand Eye Institute /ID# 256337

    Deerfield Beach, Florida

  • National Ophthalmic Research Institute /ID# 256344

    Fort Myers, Florida

  • Vitreoretinal Associates, P.A. /ID# 256266

    Gainesville, Florida

  • Florida Retina Consultants /ID# 256321

    Lakeland, Florida

  • Florida Retina Institute - Orlando /ID# 256373

    Orlando, Florida

  • Retina Specialty Institute /ID# 256268

    Pensacola, Florida

  • Fort Lauderdale Eye Institute /ID# 266011

    Plantation, Florida

  • Retina Vitreous Associates of Florida - St. Petersburg /ID# 256279

    St. Petersburg, Florida

  • Center for Retina and Macular Disease /ID# 256335

    Winter Haven, Florida

  • Georgia Retina - Marietta /ID# 256264

    Marietta, Georgia

  • Retina Consultants of Hawaii /ID# 256278

    ‘Aiea, Hawaii

  • Northwestern Memorial Hospital - Department of Ophthalmology /ID# 256379

    Chicago, Illinois

  • University Retina and Macula Associates /ID# 256288

    Lemont, Illinois

  • University Retina and Macula Associates /ID# 256287

    Oak Forest, Illinois

  • Illinois Retina Associates - Oak Park /ID# 256375

    Oak Park, Illinois

  • Springfield Clinic - First /ID# 256371

    Springfield, Illinois

  • Retina Partners Midwest, PC /ID# 256277

    Indianapolis, Indiana

Showing 40 of 181 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.